Hyperopic laser-assisted in situ keratomileusis results with LADARVision, Visx Star S2, and Visx Star S3.
To compare the LADARVision (LV), Visx Star S3 (S3), and Visx Star S2 (S2) excimer lasers in the treatment of spherical hyperopia and hyperopic astigmatism with laser-assisted in situ keratomileusis. A parallel, consecutive, three-surgeon, cohort comparison was performed at Zale Lipshy University Hospital, Laser Center for Vision, The University of Texas Southwestern Medical Center at Dallas, Texas for consecutive cases between January 2001 and October 2001. Treatment outcomes of 105 hyperopic eyes with manifest refraction spherical equivalents of up to +6.50 diopters and astigmatism up to 3.75 diopters were compared. Forty-one eyes were treated with LV; 25 eyes were treated with S3; and 39 eyes were treated with S2. Outcome measures included uncorrected visual acuity, best spectacle-corrected visual acuity, predictability, and stability of treatments at 1 week and 1, 3, and 6 months. All three lasers were comparable in terms of refractive stability and predictability. The LV group had consistently better uncorrected visual acuities than did the S2 and S3 groups during the follow-up period. At 6 months, the LV group had statistically significantly better visual results than the S3 group at the 20/25 and 20/20 levels, whereas the only significant difference between the LV and S2 groups was at the 20/25 level. Better visual outcomes were achieved with S2 than with S3, but the differences were not statistically significant. No eye lost more than one line of best spectacle-corrected visual acuity. Predictability and stability of hyperopic laser-assisted in situ keratomileusis treatments with all three lasers were comparable. Visual results with LV at 6 months were statistically significantly better than those with S3 and S2.